Efficacy and Safety Evaluation of Alirocumab in Patients With Heterozygous Familial Hypercholesterolemia or High Cardiovascular Risk Patients With Hypercholesterolemia on Lipid Modifying Therapy (ODYSSEY JAPAN)

NCT02107898 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

216

Enrollment

INDUSTRY

Sponsor class

Conditions

Hypercholesterolemia

Interventions

DRUG: Placebo (for alirocumab)
DRUG: Alirocumab
DRUG: Lipid-Modifying Therapy (LMT)

Sponsor

Sanofi

Collaborators

[object Object]